Atea Pharmaceuticals, Inc. Shareholders' Equity
Atea Pharmaceuticals, Inc. (AVIR) had Shareholders' Equity of $204.16 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-12
- 2026-06-30: Stockholders' Equity Attributable to Parent $204.16M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $233.71M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $275.43M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $315.78M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $204.16M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $233.71M 10-Q · filed 2026-08-12 |
| 2025-12-31 | $275.43M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $315.78M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $364.42M 10-Q · filed 2026-08-12 |
| 2025-03-31 | $411.08M 10-Q · filed 2026-08-12 |
| 2024-12-31 | $438.87M 10-Q · filed 2026-08-12 |
| 2024-09-30 | $458.52M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $476.47M 10-Q · filed 2025-11-12 |
| 2024-03-31 | $504.37M 10-Q · filed 2025-11-12 |
| 2023-12-31 | $555.19M 10-K · filed 2026-03-05 |
| 2023-09-30 | $581.73M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $602.35M 10-Q · filed 2024-11-07 |
| 2023-03-31 | $618.18M 10-Q · filed 2024-11-07 |
| 2022-12-31 | $640.57M 10-K · filed 2025-03-06 |
| 2022-09-30 | $663.19M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $660.46M 10-Q · filed 2023-11-08 |
| 2022-03-31 | $679.88M 10-Q · filed 2023-11-08 |
| 2021-12-31 | $710.08M 10-K · filed 2024-02-28 |
| 2021-09-30 | $581.45M 10-Q · filed 2022-11-07 |
| 2021-06-30 | $597.86M 10-Q · filed 2022-11-07 |
| 2021-03-31 | $586.26M 10-Q · filed 2022-11-07 |
| 2020-12-31 | $547.80M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$76.51M 10-Q · filed 2021-11-12 |
| 2020-06-30 | -$63.13M 10-Q · filed 2021-11-12 |
| 2020-03-31 | -$53.37M 10-Q · filed 2021-11-12 |
| 2019-12-31 | -$49.57M 10-K · filed 2023-02-28 |
| 2019-09-30 | -$45.09M 10-Q · filed 2020-12-10 |
| 2019-06-30 | -$41.62M 10-Q · filed 2020-12-10 |
| 2019-03-31 | -$38.21M 10-Q · filed 2020-12-10 |
| 2018-12-31 | -$36.16M 10-K · filed 2022-02-28 |
| 2017-12-31 | -$27.51M 10-K · filed 2021-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |